From Boston to the Saclay cluster: Servier is present in two of the world’s leading innovation hubs! These strategic locations have not been established by chance: being part of a world-renowned innovation ecosystem offers a unique opportunity to bring together our Group’s potential for innovation, and a scientific cluster of excellence, within a high-potential ecosystem that offers the best framework for the development of therapeutic projects for the benefit of patients.
Boston-Cambridge: a world-renowned innovation hub
Servier has been part of the Boston-Cambridge ecosystem for six years. Developing at the heart of such a dynamic research and innovation hub enables us to benefit from world-renowned expertise and work alongside leading institutions with the ultimate goal of offering new therapeutic solutions that meet patients’ needs.
William Sellers, distinguished cancer scientist, member of the Broad Institute of MIT and the prestigious Harvard University, where he leads the cancer program, and Dr Nabeel Bardeesy, associate professor of medicine at the Massachusetts General Hospital Cancer Center and Harvard Medical School, and associate member of the Broad Institute, look back on the benefits of developing within the Boston-Cambridge ecosystem in a groundbreaking podcast: Tell me a story | World Capital for Innovation (servier.com)
Discover the podcast
Paris-Saclay: soon to be Europe’s leading innovation hub?
Since 2023, Servier’s French R&D teams have been grouped together at the Paris-Saclay platform in our all-new R&D Institute.
Ranked as one of the top eight clusters for innovation worldwide, along with Silicon Valley, Beijing, Boston and Silicon Wadi in Israel, Paris-Saclay has top-tier international influence.
The campus offers a unique environment for Servier’s teams. It is home to key names in research, including the CNRS and CEA, as well as renowned universities, such as Paris-Saclay University and École Polytechnique graduate school, alongside international companies and startups. Our presence helps to multiply synergies by aligning our innovation potential with that of other players.
The Servier Research and Development Institute in Paris-Saclay is also home to Spartners by Servier by BioLabs, a major start-up incubator dedicated to innovative young companies in the healthcare sector. The 1,850 m² space has been designed to accommodate up to 110 people, i.e. around 15 start-ups, renewed on average every two years. Servier has designed this incubator to share know-how and expertise between our teams and those of the incubated start-ups.
Paris-Saclay University is the first French university in the world’s top 15. In 2024, it reached 12th place in the prestigious Shanghai ranking.
High-performing R&D to serve patient needs
At Servier, our ambition is clear: to strengthen our leadership position in selecting therapeutic areas, especially rare cancers. To achieve this goal, we are focusing our research efforts, leveraging open innovation and AI. Day in, day out, our teams work tirelessly to discover and develop medicines where patient needs are not yet adequately covered.
20%
We invest over 20% of our revenue from brand-name medicines in R&D each year.